- Home
- CALX vs CNTA Comparison
CALX vs CNTA Comparison
Compare CALX & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CALX | CNTA |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CALX | CNTA |
|---|---|---|
| Price | $47.73 | $39.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $74.75 | $42.00 |
| AVG Volume (30 Days) | 817.9K | ★ 4.2M |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | 29.13 |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $510,367,000.00 | $15,000,000.00 |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $13.75 | N/A |
| P/E Ratio | $189.92 | ★ N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $32.55 | $10.95 |
| 52 Week High | $71.22 | $40.26 |
Technical Indicators
Market Signals| Indicator | CALX | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 76.90 |
| Support Level | $44.15 | $24.80 |
| Resistance Level | $56.02 | $40.26 |
| Average True Range (ATR) | 2.13 | 1.07 |
| MACD | -0.11 | 0.80 |
| Stochastic Oscillator | 31.98 | 96.49 |
Price Performance
Historical ComparisonAbout CALX Calix Inc
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.